
Tumor mutational burden (TMB) is an important clinical marker used to potentially allocate patients for immune therapy. We estimated TMB before and after treatment in 35 paired samples from patients with glioblastoma. Surprisingly, relapse samples presented with a low degree of tumor purity, making intersampling comparison of TMB unreliable. We therefore developed a computational method to adjust for tumor purity in exome sequencing data and found comparison reliable in 27 paired samples. The underexplored role of tumor purity should be included in the development of a standardized method for TMB evaluation in order to stratify clinical data analysis and the evaluation of cancer treatment strategies.
Like
Save
Share